On Tuesday, Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares declined -5.06% to $3.38.
Idera Pharmaceuticals Inc (IDRA) declared that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors (TLRs) 7, 8 and 9, for the treatment of diffuse large B-cell lymphoma (DLBCL).
Idera is presently conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation (ClinicalTrials.gov identifier NCT02252146). Preclinical studies have shown that in B-cell lymphomas characterized by the MYD88 L265P oncogenic mutation, counting DLBCL, TLR signaling is over-activated, thereby enabling tumor cell survival and proliferation. As a TLR antagonist, IMO-8400 inhibits TLR signaling.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States.
Genetic Technologies Limited (ADR) (NASDAQ:GENE)’s shares dropped -5.01% to $4.93.
Genetic Technologies Limited (ADR) (GENE) declare that a further two (2) new breast health centres will start to offer BREVAGenplus® to their at-risk patients in a systematic fashion. This is in addition to the six (6) breast health centres that the Company formerly declared were set to adopt BREVAGenplus, of which all six (6) have in fact offered samples during the March 2015 quarter.
With an additional number of new breast health centres predictable to follow suit later in calendar year 2015, the Company reiterates that it anticipates sales growth to accelerate in the second half of calendar 2015 and beyond.
Genetic Technologies Limited provides genetic testing services primarily in Australia and the United States. It offers a range of genetic tests for breast and ovarian cancer, bowel and uterine cancer, and prostate cancer; neurogenetic diagnostic assays; and gene testing for Epilepsy SCN1A gene related disorders.
At the end of Tuesday’s trade, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)‘s shares dipped -4.95% to $18.06.
Momenta Pharmaceuticals, Inc. (MNTA) presented new data from studies conducted as part of the ANDA submission for once daily Glatopa (glatiramer acetate injection) at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C. The posters presented provide examples of a selection of methods the Company utilized to show the equivalence of Glatopa and once daily COPAXONE 20 mg.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases.
Warren Resources, Inc. (NASDAQ:WRES), ended its Tuesday’s trading session with -4.88% loss, and closed at $1.17.
Hormel Foods Corporation (HRL) offered additional information regarding the anticipated influence of recent avian influenza outbreaks on its Jennie-O Turkey Store segment.
Highly pathogenic H5N2 avian influenza has been detected at multiple turkey farms that supply Jennie-O Turkey Store, resulting in the loss of affected flocks and temporary quarantine of farms in the area until a full cleaning process is accomplished. Lower turkey supply is predictable to influence plant operations and cause reduced sales volumes as the year progresses.
Warren Resources, Inc. an independent energy company holds in the exploration, development, and production of domestic onshore crude oil and gas reserves. The company primarily focuses on the exploration and development of waterflood oil recovery projects in the Wilmington field within the Los Angeles Basin of California; Marcellus Shale project in northeastern Pennsylvania; and coalbed methane natural gas properties located in the Rocky Mountain region.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
